Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends - 2012
Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends - 2012 Summary GlobalData's "Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends - 2012" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on Partnerships, Licensing Agreements, M&As, Equity/Debt Offerings, Private Equity and Venture Financing transactions registered in the pharmaceutical and healthcare industry in 2012. The report presents detailed comparative data on the number of deals and their value in the past five years categorized into deal types, segments, and geographies. Additionally, the report provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry. Data presented in this report is derived from GlobalData's proprietary in-house deals database and primary and secondary research. Scope Analysis of the market trends for the pharmaceutical industry in the global arena. Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments. Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry. Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As. Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry. Analysis of partnership and licensing deals based on clinical stage of development of products. Summary of the pharmaceutical deals globally in the last five years. Information on the top deals happened in the pharmaceutical industry. Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs. Reasons to buy Enhance your decision making capability in a more rapid and time sensitive manner. Find out the major deal performing segments for investments in your industry. Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets. Identify companies that are aggressively looking to raise capital in the market Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry. Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies. Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening. Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry. Identify growth segments and opportunities in each region within the industry. Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends - 2012
table Of Contents
1 Table Of Contents 1 Table Of Contents 2 1.1 List Of Tables 4 1.2 List Of Figures 6 2 Pharmaceutical & Healthcare, Global, Deals Summary 9 2.1 Pharmaceutical & Healthcare, Global, Deals Analysis, 2012 9 2.1.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, 2012 By Quarter 11 2.2 Pharmaceuticals & Healthcare, Global, By Type, Number Of Deals, 2012 13 2.3 Pharmaceuticals & Healthcare, Global, By Type, Deal Values, 2012 14 2.4 Pharmaceuticals & Healthcare, Global, Top Deals, 2012 15 2.5 Pharmaceuticals & Healthcare, Top Deals, Global, Summaries, 2012 16 2.5.1 Abbott Completes Private Placement Of Notes For $14.7 Billion 16 2.5.2 Nestle Completes Acquisition Of Pfizer Nutrition From Pfizer For $11.85 Billion 16 2.5.3 Roche Revises Offer Price To Acquire Illumina For Up To $8.2 Billion 16 2.5.4 Aetna Receives Shareholders Approval To Acquire Coventry Health Care For $7.3 Billion 17 2.5.5 Walgreen Acquires 45% Stake In Alliance Boots From Kkr And Axa Private Equity For $6.7 Billion 17 2.5.6 Watson Pharma Completes Acquisition Of Actavis Group For $5.92 Billion 18 2.5.7 Bristol-myers Squibb Completes Acquisition Of Amylin Pharma For $5.3 Billion 19 2.5.8 Glaxosmithkline Completes Public Offering Of Notes For $5 Billion 19 2.5.9 Unitedhealth Completes Acquisition Of 60% Stake In Amil Participacoes 19 2.5.10 Wellpoint Completes Acquisition Of Amerigroup For $4.9 Billion 20
3 Pharmaceuticals & Healthcare, Global, Top Deal Makers, 2012 21
4 Pharmaceuticals & Healthcare, Global, Deal Summary, By Type 22 4.1 Pharmaceuticals & Healthcare, Global, M&a, 2012 22 4.1.1 Pharmaceuticals & Healthcare, Global, M&a, 2012 By Quarter 23 4.1.2 Top M&a Deals In 2012 24 4.1.3 Pharmaceuticals & Healthcare, Global, M&a Deals, By Therapy Area, 2012 25 4.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2012 26 4.2.1 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2012 By Quarter 27 4.2.2 Pharmaceuticals & Healthcare, Global, Ipo Deals, 2012 28 4.2.3 Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, 2012 30 4.2.4 Pharmaceuticals & Healthcare, Global, Pipe Deals, 2012 32 4.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, By Therapy Area, 2012 34 4.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, 2012 35 4.3.1 Pharmaceuticals & Healthcare, Global Debt Offerings, 2012 By Quarter 36 Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends - 2012
4.3.2 Pharmaceuticals & Healthcare, Global, Public Debt Offerings, 2012 37 4.3.3 Pharmaceuticals & Healthcare, Global, Private Debt Placements, 2012 38 4.3.4 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, By Therapy Area, 2012 39 4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2012 40 4.4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2012 By Quarter 41 4.4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, By Therapy Area, 2012 43 4.4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, By Upfront & Milestone Payments And Deal Value (us$ M), 2012 44 4.4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, By Therapy Area, By Upfront & Milestone Payments And Deal Values (us$ M), 2012 45 4.4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, By Phase, Number Of Deals, 2012 46 4.4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, By Phase, Deal Values (us$ M), 2012 47 4.4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, By Phase, By Upfront & Milestone Payments And Deal Values (us$ M), 2012 48 4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2012 51 4.5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2012 By Quarter 52 4.5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreements, By Therapy Area, 2012 53 4.5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreements, By Upfront & Milestone Payments And Deal Value (us$ M), 2012 54 4.5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, By Therapy Area, By Upfront & Milestone Payments And Deal Values (us$ M), 2012 55 4.5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, By Phase, Total Deal Values (us$ M), 2012 56 4.5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, By Phase, Total Deal Values (us$ M), 2012 57 4.5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreements, By Phase, By Upfront & Milestone Payments And Deal Values (us$ M), 2012 58 4.6 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2012 61 4.6.1 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2012 By Quarter 62 4.6.2 Top Private Equity Deals In 2012 63 4.6.3 Pharmaceuticals & Healthcare, Global, Private Equity Deals, By Therapy Area, 2012 64 4.7 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, 2012 65 4.7.1 Pharmaceuticals & Healthcare, Global, Venture Financing Deals, 2012 By Quarter 66 4.7.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, By Stage Of Financing, 2012 67 4.7.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, By Stage Of Financing, 2012 68 4.7.4 Pharmaceuticals & Healthcare, Global, Venture Capital, By Therapy Area, 2012 69 4.7.5 Pharmaceuticals & Healthcare, Global, Top Vc Backed Companies, Last One Year 70 4.7.6 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, 2012 71 4.7.7 Top Venture Financing Deals In 2012 72
5 Pharmaceuticals & Healthcare, Global, Deal Summary, By Market 73 5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2012 73 Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends - 2012
5.1.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2012 By Quarter 75 5.1.2 Oncology - Deals Of The Year 76 5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2012 78 5.2.1 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2012 By Quarter 79 5.2.2 Central Nervous System - Deals Of The Year 80 5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2012 82 5.3.1 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2012 By Quarter 83 5.3.2 Infectious Disease - Deals Of The Year 84 5.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2012 86 5.4.1 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2012 By Quarter 87 5.4.2 Immunology - Deals Of The Year 88 5.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2012 90 5.5.1 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2012 By Quarter 91 5.5.2 Cardiovascular - Deals Of The Year 92 5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2012 93 5.6.1 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2012 By Quarter 94 5.6.2 Metabolic Disorders - Deals Of The Year 95 5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2012 97 5.7.1 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2012 By Quarter 98 5.7.2 Gastrointestinal - Deals Of The Year 99
6 Pharmaceuticals & Healthcare, Deal Summary, By Geography 101 6.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2012 101 6.1.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2012 By Quarter 102 6.1.2 North America - Deals Of The Year 103 6.2 Pharmaceuticals & Healthcare, European Region Deals, 2012 106 6.2.1 Pharmaceuticals & Healthcare, Europe, Deals, 2012 By Quarter 107 6.2.2 Europe - Deals Of The Year 108 6.3 Pharmaceuticals & Healthcare, Asia-pacific Region, Deals, 2012 110 6.3.1 Pharmaceuticals & Healthcare, Asia-pacific Region Deals, 2012 By Quarter 111 6.3.2 Asia-pacific - Deals Of The Year 112 6.4 Pharmaceuticals & Healthcare, Rest Of The World (row) Deals, 2012 114 6.4.1 Pharmaceuticals & Healthcare, Rest Of The World Deals, 2012 By Quarter 115 6.4.2 Rest Of The World - Deals Of The Year 116
7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 117 7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&a, 2012 117 7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, 2012 118
8 Further Information 119 Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends - 2012
8.1 Methodology 119 8.2 About Globaldata 120 8.3 Contact Us 120 8.4 Disclosure Information 120 8.5 Disclaimer 120 About Us: Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge. Contact: ResearchMoz 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Blog: http://researchmoz.blogspot.com/ Website: http://www.researchmoz.us/
Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends - 2012